Posted by Michael Wonder on 04 May 2026
Korea covers Takeda’s Takhzyro, but most patients may still be left out: experts
26 March 2026 - Korea has granted reimbursement for Takeda’s hereditary angioedema drug Takhzyro (lanadelumab), but physicians say most patients may still face barriers to access.
Korea has about 300 identified hereditary angioedema patients, they said, though the real number may be closer to 1,000 because so many remain undiagnosed. Under the current criteria, only about 10% are likely to qualify.
